We are live on
!
Find out more
PCH
Polar Capital Holdings Portfolio holdings
AUM
$42.4B
1-Year Est. Return
181.11%
This Fund
S&P 500
This Quarter
Est. Return
-0.56%
1 Year Est. Return
+181.11%
3 Year Est. Return
+584.8%
5 Year Est. Return
+777.19%
10 Year Est. Return
–
AUM
$15.7B
AUM Growth
-$1.33B
(-7.8%)
Cap. Flow
-$153M
Cap. Flow
% of AUM
-0.98%
Top 10 Holdings %
Top 10 Hldgs %
39.89%
Holding
471
New
38
Increased
139
Reduced
173
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$70.7M |
| 2 |
Meta Platforms (Facebook)
META
|
+$66.5M |
| 3 |
Becton Dickinson
BDX
|
+$61.6M |
| 4 |
GitLab
GTLB
|
+$58.7M |
| 5 |
Teradyne
TER
|
+$58.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$85.2M |
| 2 |
Steris
STE
|
+$78.2M |
| 3 |
CVS Health
CVS
|
+$62.9M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$61.9M |
| 5 |
FIVE9
FIVN
|
+$58.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.08% |
| 2 | Industrials | 22.24% |
| 3 | Healthcare | 19.2% |
| 4 | Financials | 15.72% |
| 5 | Communication Services | 5.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
126
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $23.1M | 0.15% |
1,250,000
-250,000
| -17% | -$3.92M |
|
127
SiTime
SITM
$16.8B
| $23.1M | 0.15% |
293,188
-93,308
| -24% | -$12M |
|
128
Alnylam Pharmaceuticals
ALNY
$33.5B
| $23M | 0.15% |
115,000
-98,079
| -46% | -$18.7M |
|
129
Pliant Therapeutics
PLRX
$72.4M
| $23M | 0.15% |
+1,100,000
| New | +$21M |
|
130
AtriCure
ATRC
$2.84B
| $22.4M | 0.14% |
573,345
+44,487
| +8% | +$2.04M |
|
131
Ametek
AME
$55.5B
| $21.9M | 0.14% |
193,129
-1,352
| -0.7% | -$162K |
|
132
Alcon
ALC
$32.7B
| $21.7M | 0.14% |
356,621
-6,203
| -2% | -$430K |
|
133
Intuitive Surgical
ISRG
$134B
| $21.7M | 0.14% |
115,528
+19,289
| +20% | +$4.14M |
|
134
Intercontinental Exchange
ICE
$88.4B
| $21.4M | 0.14% |
237,169
-1,661
| -0.7% | -$167K |
|
135
Wells Fargo
WFC
$268B
| $21.3M | 0.14% |
529,373
+100,716
| +23% | +$4.33M |
|
136
Humana
HUM
$48.9B
| $20.8M | 0.13% |
42,921
+5,921
| +16% | +$2.88M |
|
137
Shopify
SHOP
$172B
| $20.6M | 0.13% |
763,986
-106,874
| -12% | -$3.64M |
|
138
Centene
CNC
$34.3B
| $19.9M | 0.13% |
255,399
+6,028
| +2% | +$539K |
|
139
Cenovus Energy
CVE
$61.4B
| $19.2M | 0.12% |
1,016,844
-4,243
| -0.4% | -$75.4K |
|
140
Canadian Natural Resources
CNQ
$104B
| $19.2M | 0.12% |
670,236
-42,834
| -6% | -$1.11M |
|
141
BioMarin Pharmaceuticals
BMRN
$12.9B
| $19.1M | 0.12% |
225,000
| – | – |
|
142
Ovintiv
OVV
$17.6B
| $18.8M | 0.12% |
407,854
+35,000
| +9% | +$1.67M |
|
|
143
Neurocrine Biosciences
NBIX
$16B
| $18.5M | 0.12% |
173,946
-610,341
| -78% | -$61.9M |
|
144
Adicet Bio
ACET
$90.8M
| $18.4M | 0.12% |
80,854
-15,625
| -16% | -$3.97M |
|
145
LPL Financial
LPLA
$27.2B
| $18.3M | 0.12% |
83,673
-36,589
| -30% | -$7.78M |
|
|
FISV
146
Fiserv Inc
FISV
$27.1B
| $18M | 0.11% |
192,538
+34,600
| +22% | +$3.53M |
|
147
AptarGroup
ATR
$7.94B
| $18M | 0.11% |
189,372
-285,351
| -60% | -$29.7M |
|
148
Rhythm Pharmaceuticals
RYTM
$7.05B
| $17.5M | 0.11% |
+714,739
| New | +$13.3M |
|
149
SS&C Technologies
SSNC
$18.8B
| $17.1M | 0.11% |
357,375
-40,385
| -10% | -$2.33M |
|
150
Service Corp International
SCI
$11.2B
| $16.9M | 0.11% |
291,821
-58,598
| -17% | -$3.86M |
|
Similar funds
GAM
SAM
Polar Capital Holdings's Q3 2022 Portfolio in Review
As of Q3 2022, Polar Capital Holdings held 471 positions worth $15.7B, down 7.8% from $17B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Polar Capital Holdings's Q3 2022 filing shows 38 new, 139 increased, 173 reduced and 54 closed positions. Its largest new stake was DexCom: 834,956 shares worth $67.2M. The largest sale was Adobe, an estimated $85.2M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 31% a quarter earlier, followed by Industrials and Healthcare.
- Polar Capital Holdings's largest Q3 2022 buy was DexCom: 834,956 shares worth $67.2M.
- Polar Capital Holdings added most to Meta Platforms (Facebook) in Q3 2022, an estimated $66.5M increase.
- Polar Capital Holdings's biggest Q3 2022 reduction was Neurocrine Biosciences, cutting an estimated $61.9M.
- Polar Capital Holdings fully exited Adobe in Q3 2022, selling an estimated $85.2M.
- Polar Capital Holdings's ten largest holdings make up 40% of its $15.7B portfolio in Q3 2022.
- Polar Capital Holdings opened 38 new positions and closed 54 in Q3 2022.
- Polar Capital Holdings's portfolio value fell 7.8% quarter-over-quarter to $15.7B.
Based on Polar Capital Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.